BREAKWATER Study for BRAF V600E Mutated Colorectal Cancer – Encorafenib + Cetuximab + Chemotherapy

Welcome back to the Oncology Brothers podcast! In this second episode of our three-part series on colorectal cancer, we dived deep into the BRAF V600E mutation and its implications for metastatic colorectal cancer treatment.Listen us on:Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966Follow us on social media:X/Twitter: https://twitter.com/oncbrothersInstagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/Join us as we discussed:The prevalence and outcomes associated with BRAF V600E mutationsRecent advances in treatment options, including the BREAKWATER studyThe significance of biomarker testing and how it influences treatment decisionsThe new standard of care combining Encorafenib and Cetuximab with chemotherapyManagement of overlapping side effects from targeted therapiesStrategies for sequencing treatments in patients with MSI-high diseaseThis episode is packed with valuable information for healthcare professionals and anyone interested in the latest advancements in colorectal cancer treatment. Don't miss out on the critical insights shared by our expert guest!Be sure to check out Part 1 of our series for an overview of the colorectal cancer treatment landscape, and stay tuned for Part 3, where we will focus on toxicity management and practical clinical pearls.Subscribe to our channel for more oncology insights and updates!This discussion was in support of an independent educational grant provided by Pfizer#ColorectalCancer,#BRAFV600E, #BREAKWATER, #TargetedTherapy, #OncologyBrothers